Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.
about
In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacinMICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosisComparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sourcesComparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycinMycobacteria and the new quinolonesAmikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige miceIn vitro susceptibilities of Mycobacterium tuberculosis to 10 antimicrobial agentsBroth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndromeComparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige miceInhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophagesAnti-Mycobacterium avium activity of quinolones: in vitro activitiesCiprofloxacin susceptibility testing by MIC and disk elution of drug-resistant Mycobacterium tuberculosis and Mycobacterium avium complexSusceptibility testing of Mycobacterium avium complex isolatesMycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activityAntibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulationMulticenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.Synthesis, characterization, and biological evaluation of some new functionalized terphenyl derivatives.Fluoroquinolones and tuberculosis.Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application.Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria.Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods.Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.Polyclonal Mycobacterium avium infections in patients with AIDS: variations in antimicrobial susceptibilities of different strains of M. avium isolated from the same patient.Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates.Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan.Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.Mode of action, and in vitro and in vivo activities of the fluoroquinolones.Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents.Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages.Synthesis of some nucleosides derivatives from L- rhamnose with expected biological activity.Triggered release of ciprofloxacin from nanostructured agglomerated vesicles.In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.Uptake of quinolones by in-vitro human monocyte derived macrophages.Synthesis and antimicrobial activity of 1,2,3-triazoles containing quinoline moiety.Macrolides: problems and promises.Synthesis of Some Novel 2,4-Disubstituted Thiazoles as Possible Antimicrobial AgentsSpectrophotometric Determination of Ofloxacin and Lomefloxacin Hydrochloride with Some Sulphonphthalein Dyes
P2860
Q28328860-5F31B168-872C-4F14-97CF-DC0696B8CF2DQ28329425-291DF5EA-8EDF-4FFB-B35C-371E50437C6BQ28335823-5E8B28AF-7C58-4F80-9FDF-903477841A40Q28341927-386D8A80-425A-4F20-844D-FD5DA490C750Q28342507-8F4848C0-BF6C-41C0-BF4C-9C88EFB3E1FAQ28356424-129F3E22-D4CA-4EE1-AA97-83AF190BECE6Q28361078-E9BA65E5-1358-47B2-8806-8A3854645C53Q28361676-F6ACF985-D2F6-4B65-A25D-6972E177C25AQ28369086-3E2C90D3-F3AA-4A4F-89E9-988E939E88ACQ28369387-9E1AECC0-DFD8-4A09-8684-18105077A987Q28378348-584F37C6-19B3-400A-8EBB-A3D324100FA1Q28378596-214B3C07-52C6-4681-B59E-745DCFEDD7F5Q28379189-B7C78B7B-B92C-4729-BD25-F514D8FDB747Q28486793-6CFFAEBB-E0A4-4DCD-914F-CF5B15769F18Q33690455-F78DE7C8-F169-4666-832D-1D67682405D8Q33962909-7B3F29E4-BB20-468A-BE18-0C30FEE36EE6Q34393667-0305F233-281F-4F0C-88C8-37F823AD48C8Q34519143-A18680E8-1B94-4F2B-BBB8-9164D614CC1CQ34687048-5AC1FB4E-25BD-451B-8102-343A3C240EA7Q35136593-CA66EBEA-FB48-470C-89BD-34274D17B82FQ35541583-8C322095-27BC-48B0-9469-C2AF46D64EADQ35543136-38762F0B-00FD-4715-A55A-CAAFB5E50715Q36075800-09754B5F-5A30-49AF-8205-88E712271622Q36521116-6676EF1C-A654-4C67-AC86-B4581BBC8C74Q36758404-427C55B9-CEDD-459E-935B-1CECFC8EF28DQ37133132-674C56AA-9CF5-40AD-99C0-61ADE0D8A2A1Q38295637-D77C2033-4A7E-4928-A9E1-672E55F795EDQ39214819-F0CA9673-629F-4EBE-B9B1-871CA918499DQ39637667-F4716816-F2B5-4A18-ADBE-34F786BB25A2Q39827520-26668182-7ABA-4DF5-B941-1710EB728A24Q40285262-E2992F0D-D166-457A-9978-8BA32C0FB0FAQ41963424-E5C67BD5-39F1-40E3-88DA-E0A244D3542AQ41984283-8A2AB549-A488-41EB-9948-AB7E00CD8AB3Q42208714-6CE73C5D-7F9A-494D-B99E-929731A56027Q42504782-952F6769-1E7B-4ACB-A78B-517A1A203D89Q42769942-1A1E67E2-9F57-4A25-8266-ABBE2FD70490Q54388935-B8D9FC4D-6AD6-4EF5-80D8-339BF2CAA0A8Q57714648-6E5F49F7-3549-4D08-8F7B-2C3CD232FAE9Q58245594-B3FC9335-234A-49DF-8D68-FB7E0EE94847
P2860
Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.
description
1986 nî lūn-bûn
@nan
1986 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի մարտին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Comparative in vitro activitie ...... d Mycobacterium intracellulare
@nl
Comparative in vitro activitie ...... Mycobacterium intracellulare.
@ast
Comparative in vitro activitie ...... Mycobacterium intracellulare.
@en
type
label
Comparative in vitro activitie ...... d Mycobacterium intracellulare
@nl
Comparative in vitro activitie ...... Mycobacterium intracellulare.
@ast
Comparative in vitro activitie ...... Mycobacterium intracellulare.
@en
prefLabel
Comparative in vitro activitie ...... d Mycobacterium intracellulare
@nl
Comparative in vitro activitie ...... Mycobacterium intracellulare.
@ast
Comparative in vitro activitie ...... Mycobacterium intracellulare.
@en
P2860
P356
P1476
Comparative in vitro activitie ...... Mycobacterium intracellulare.
@en
P2093
P2860
P304
P356
10.1128/AAC.29.3.386
P407
P577
1986-03-01T00:00:00Z